EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

LINE-1 retrotransposition and its deregulation in cancers: implications for therapeutic opportunities

Carlos Mendez-Dorantes iD, Kathleen H Burns iD

Genes & Development · 2023-11 · 37 (21-24) · 948-967

DOI: 10.1101/gad.351051.123 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Genes & Development, online erschienen am 13.12.2023. Verfasst von Carlos Mendez-Dorantes und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Dana-Farber Cancer Institute, Boston, Massachusetts 02115, USA; kathleenh_burns@dfci.harvard.edu carlos_mendez-dorantes@dfci…. Hauptthemen laut MEDLINE: Long Interspersed Nucleotide Elements, Neoplasms. Die Arbeit wurde bisher 125-mal zitiert (Crossref) und nennt 195 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NINDS NIH HHS, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Long interspersed element 1 (LINE-1) is the only protein-coding transposon that is active in humans. LINE-1 propagates in the genome using RNA intermediates via retrotransposition. This activity has resulted in LINE-1 sequences occupying approximately one-fifth of our genome. Although most copies of LINE-1 are immobile, ∼100 copies are retrotransposition-competent. Retrotransposition is normally limited via epigenetic silencing, DNA repair, and other host defense mechanisms. In contrast, LINE-1 overexpression and retrotransposition are hallmarks of cancers. Here, we review mechanisms of LINE-1 regulation and how LINE-1 may promote genetic heterogeneity in tumors. Finally, we discuss therapeutic strategies to exploit LINE-1 biology in cancers.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Long Interspersed Nucleotide ElementsNeoplasmsHumansRNAProteinsEpigenesis, Genetic

Stichwörter der Autor:innen

LINE-1 retrotransposonsepigeneticsgenome instability

Substanzen

RNAProteins

Autor:innen und Institutionen

  • Department of Pathology, Dana-Farber Cancer Institute, Boston, Massachusetts 02115, USA; kathleenh_burns@dfci.harvard.edu carlos_mendez-dorantes@dfci.harvard.edu.
  • Department of Pathology, Harvard Medical School, Boston, Massachusetts 02115, USA.
  • Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, Massachusetts 02142, USA.

ORCID-Profile: Carlos Mendez-Dorantes, Kathleen H Burns

Förderung

  • NCI NIH HHS
  • NINDS NIH HHS
  • National Institutes of Health
  • Dana-Farber Cancer Institute
  • Jane Coffin Childs Memorial Fund for Medical Research

Zitieren

APA

Mendez-Dorantes, C., & Burns, K. H. (2023). LINE-1 retrotransposition and its deregulation in cancers: implications for therapeutic opportunities. Genes & Development, 37(21-24), 948-967. https://doi.org/10.1101/gad.351051.123

Vancouver

Mendez-Dorantes C, Burns KH. LINE-1 retrotransposition and its deregulation in cancers: implications for therapeutic opportunities. Genes & Development. 2023;37(21-24):948-967. doi:10.1101/gad.351051.123

BibTeX
@article{MendezDorantes2023,
  author = {Mendez-Dorantes, Carlos and Burns, Kathleen H},
  title = {LINE-1 retrotransposition and its deregulation in cancers: implications for therapeutic opportunities},
  journal = {Genes & Development},
  year = {2023},
  volume = {37},
  number = {21-24},
  pages = {948--967},
  doi = {10.1101/gad.351051.123}
}
Kostenlos starten →